RCM
ACRS icon

Requisite Capital Management’s Aclaris Therapeutics ACRS Stock Holding History

Requisite Capital Management’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-45,000
Closed -$708K – 60
2022
Q3 		$708K Hold
45,000
– – 0.24% 19
2022
Q2 		$628K Buy
+45,000
New +$631K 0.21% 26

Other funds holding ACRS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Requisite Capital Management's ACRS Position: Q4 2022 in Review

Requisite Capital Management sold out of Aclaris Therapeutics (ACRS) in Q4 2022, closing a stake of 45,000 shares — an estimated $708K sold.

Requisite Capital Management first reported a position in ACRS in Q2 2022 and held it in 2 quarters. The position peaked at $708K in Q3 2022. 128 funds tracked by Wall St. Rank hold ACRS as of Q4 2022.

  • Requisite Capital Management reported no remaining Aclaris Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Requisite Capital Management sold 45,000 Aclaris Therapeutics shares in Q4 2022, an estimated $708K.
  • Requisite Capital Management first reported a position in Aclaris Therapeutics in Q2 2022 and held it in 2 quarters.
  • Requisite Capital Management's Aclaris Therapeutics position peaked at $708K in Q3 2022.
  • 128 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q4 2022.

Based on Requisite Capital Management's 13F filing for Q4 2022, filed 2 Feb 2023.